Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumabderuxtecan, for treating EGFR-mutated non-small cell lung ...
Results that may be inaccessible to you are currently showing.